Shingrix (varicella zoster vaccine [recombinant], adjuvanted) from Glaxosmithkline plc (GSK) sailed through a hearing by the FDA's Vaccines and Related Biological Products Committee, with panelists voting 11-0 in favor of the product's efficacy and safety in people 50 years of age and beyond.